Development strategies and application of Fc fusion protein / 中华微生物学和免疫学杂志
Chinese Journal of Microbiology and Immunology
;
(12): 551-557, 2019.
Article
Dans Chinois
| WPRIM
| ID: wpr-756235
ABSTRACT
Monoclonal antibodies ( McAb ) , a rapidly expanding class of therapeutic biological products, have been widely used in the treatment of various diseases. Although antibodies have shown tre-mendous clinical value, the breadth and complexity of human diseases urge researchers to constantly develop new drugs with new modes of action rather than to confine them to monoclonal antibodies alone. Fc fusion proteins are becoming a new research hotspot and have shown great potential in the treatment of many human diseases. At present, Fc fusion proteins on the market usually take the interaction between receptors and lig-ands as the main guiding strategy to develop more safer and effective clinical drugs. This article mainly fo-cused on the ligand-receptor interaction as the drug design strategy and the application. of Fc fusion pro-teins.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Chinois
Texte intégral:
Chinese Journal of Microbiology and Immunology
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS